Anthropic announced its Bay Area biology lab, which uses AI models to run physical experiments, has discovered a novel enzyme system with properties similar to CRISPR. The discovery, made with Anthropic's Claude AI, highlights the potential of AI in biological research, though human scientists conducted the physical experiments.
The discovery highlights the accelerating integration of AI into scientific research, potentially speeding up biological discoveries and drug development, while also raising questions about AI safety and the dual-use nature of advanced AI capabilities in sensitive fields like biotechnology.
Anthropic has announced a significant discovery made by its Bay Area-based wet biology lab, which utilizes AI models to conduct physical experiments. The company revealed that its AI, Claude, identified a novel enzyme system within bacteriophage DNA that exhibits properties reminiscent of CRISPR, including the ability to "perform operations like cutting, copying, and pasting DNA." This discovery was reportedly achieved in just 21 hours of concerted effort by Claude, utilizing approximately 950 AI agents and processing 210 million tokens. However, Anthropic CEO Dario Amodei acknowledged that the discovery builds upon previous work and that similar systems have been identified by researchers at Stanford. The lab operates at biosafety risk levels BSL-1 and BSL-2 and does not handle human pathogens, with all physical experiments conducted by human scientists. This development comes amid broader discussions within the AI industry about the rapid advancement of AI capabilities and the associated risks, including potential misuse for bioterrorism, a concern previously voiced by Amodei himself.
Pick the topics you care about. Get only what matters, on your cadence.